These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intermittent bolus dosing of ceftazidime in critically ill patients. Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245 [TBL] [Abstract][Full Text] [Related]
5. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Benko AS; Cappelletty DM; Kruse JA; Rybak MJ Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Guenter SG; Iven H; Boos C; Bruch HP; Muhl E Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556 [TBL] [Abstract][Full Text] [Related]
8. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Matzke GR; Frye RF; Joy MS; Palevsky PM Antimicrob Agents Chemother; 2000 Jun; 44(6):1639-44. PubMed ID: 10817721 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. Buijk SL; Gyssens IC; Mouton JW; Van Vliet A; Verbrugh HA; Bruining HA J Antimicrob Chemother; 2002 Jan; 49(1):121-8. PubMed ID: 11751775 [TBL] [Abstract][Full Text] [Related]
10. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Boereboom FT; Ververs FF; Blankestijn PJ; Savelkoul TJ; van Dijk A Intensive Care Med; 1999 Oct; 25(10):1100-4. PubMed ID: 10551965 [TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Kashuba AD; Ballow CH; Forrest A Antimicrob Agents Chemother; 1996 Aug; 40(8):1860-5. PubMed ID: 8843294 [TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. Meyer B; Kornek GV; Nikfardjam M; Karth GD; Heinz G; Locker GJ; Jaeger W; Thalhammer F J Antimicrob Chemother; 2005 Jul; 56(1):172-9. PubMed ID: 15905303 [TBL] [Abstract][Full Text] [Related]